There is one clinical trial.
The purpose of this study is to analyze in depth the relationship of myeloid cell subpopulations during infection by Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2), the virus mediating Covid-19. Myeloid cells include neutrophils, monocytes and dendritic cells, each divided into subpopulations with different functions in immune defense and immune pathologies. The study is based on the following hypotheses: - Infection and the interferon response to infection may induce hyperactive or immunosuppressive differentiation of myeloid cells, that may be treated by specific inhibitors. - Some myeloid cell subpopulations currently identified in our laboratories might be markers for Covid-19 prognosis. - Alternative receptors may be present on myeloid cells, inducing the cytokine storm, a target for therapy. - The expression of Interferon (IFN) receptor and IFN responding genes on myeloid cells and on respiratory epithelial cells may correlate with prognosis and indicate potential treatment targets. - Interferon responses are known to be skewed during Covid-19, but some IFN subtype polymorphisms may correlate with prognosis and these subtypes migt be supplemented or inhibited for therapy.
Description: Cytometric analysis of surface and intracellular molecules to identify myeloid cell sub-populations and define their function in vivoMeasure: Myeloid cell sub-population phenotype Time: Month zero-month 36
Description: Cell culture and cytometric and analyte analysis of their functions, including IFN productionMeasure: Myeloid cell functions Time: Month zero-month 36
Description: Transcriptomic and proteomic analysis of the functions of myeloid cell subtypesMeasure: Myeloid cell transcriptomic and proteomic study Time: Month zero-month 36
Description: Single cell RNA sequencing of the nasal brush productsMeasure: Transcriptomic study of nasal epithelial cells Time: Month zero-month 36
Description: High sensitivity detection by state-of-the art ELISA type methodsMeasure: Plasma analyte concentration measurement Time: Month zero-month 36
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports